SmallCaps
ASX:RHYHealth Care Equipment & ServicesHealth Care Services

Rhythm Biosciences Ltd

$0.093
$0.003 (3.13%)
Day Range
$0.091 – $0.100
52 Week Range
$0.047 – $0.280
Volume
631.63K
Avg Volume (10D)
308.54K
Market Cap
$32.91M

Price Chart

OHLC · volume · moving averages

$0.093-$0.027 (-22.50%)over 6M
Hi$0.280Lo$0.091
Price-sensitive newsVolumePrev close · 52W range

Market Statistics

Today's trading range

Open
$0.100
Previous Close
$0.096
Day High
$0.100
Day Low
$0.091
52 Week High
$0.280
52 Week Low
$0.047

Valuation

Fundamental multiples

Market Cap
32.91M
Shares Outstanding
353.87M
Price to Book
15.72

Trading Activity

Volume & order book

Volume
631.63K
Value Traded
61.02K
Bid
$0.093 × 6,162
Ask
$0.099 × 36,600

Performance

Returns across timeframes

1 Day
-9.09%
5 Day
-13.04%
13 Week
-47.37%
52 Week
61.29%
YTD
-25.93%

Technical Indicators

Momentum & moving averages

RSI (14)
33.25
50-Day SMA
$0.133
200-Day SMA
$0.134

— From the desk

Latest News

Rhythm Biosciences’ 2G ColoSTAT colorectal cancer detection kit outperforms predecessor in key testing
Biotechnology

Rhythm Biosciences’ 2G ColoSTAT colorectal cancer detection kit outperforms predecessor in key testing

Medical diagnostics company Rhythm Biosciences (ASX: RHY) has confirmed that the second version of its ColoSTAT kit for the detection of colorectal cancer has shown significant outperformance on the original. Preliminary testing of 200 patient serum samples using the new multiplex Alpha antibody kit has revealed superior analytical results compared to tests performed on the […]

Rhythm Biosciences receives UKCA mark for ColoSTAT colorectal blood test kit
Biotechnology

Rhythm Biosciences receives UKCA mark for ColoSTAT colorectal blood test kit

A simple blood test used for the detection of colorectal cancer has achieved UK Conformity Assessed (UKCA) marking for developer Rhythm Biosciences (ASX: RHY). The regulatory milestone proves the ColoSTAT kit fully conforms with the European Directives for IVD Medical Devices (98/79/EC) and moves it a step closer to commercialisation in the UK. The achievement […]

Rhythm Biosciences reports positive results for lead biomarker in blood test for colorectal cancer screening
Biotechnology

Rhythm Biosciences reports positive results for lead biomarker in blood test for colorectal cancer screening

Australian medical diagnostics company Rhythm Biosciences (ASX: RHY) has confirmed the antibodies in a lead biomarker of a blood test for the accurate and early detection of colorectal cancer have been successfully validated, stabilised and proven to be reproduceable. The biomarker can differentiate between cancerous and healthy blood samples and makes up the principal ingredient […]

Rhythm Biosciences advances development of novel colorectal cancer test
Biotechnology

Rhythm Biosciences advances development of novel colorectal cancer test

Medical diagnostics technology company Rhythm Biosciences (ASX: RHY) is continuing the development of its novel test for colorectal cancer, named ColoSTAT. As part of this work, the company says it has achieved a major technical achievement by isolating four cell lines that produce monoclonal antibodies. Rhythm said that its development of reagents is currently “ahead […]